FDA panel backs InterMune's pulmonary fibrosis drug Esbriet despite reservations
This article was originally published in Scrip
By a decisive 9-3 vote, the US FDA's advisory committee on pulmonary drugs on March 9th recommended that the agency approve the new drug application (NDA) from InterMune to market as a treatment its drug Esbriet (pirfenidone) to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF).
You may also be interested in...
Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.